Orphan designation: tazemetostat Treatment of malignant mesothelioma, 21/03/2018 Withdrawn | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 18 May 2026 - 10:41

Orphan designation: tazemetostat Treatment of malignant mesothelioma, 21/03/2018 Withdrawn

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2006

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters